Eco-pharmacology: Drug Environmental Contamination and the Role of the Pharma Industry

The presence of pharmaceutical compounds in the environment is an emerging problem that the industry can no longer ignore. Eco-pharmacology — the discipline studying the effects of drugs on ecosystems — is gaining traction in global regulatory frameworks and in the sustainability agendas of pharmaceutical companies. Understanding the origins of contamination, its documented impacts, and the ecopharmacovigilance framework is relevant for both R&D teams and business development stakeholders.

How Do Pharmaceuticals Reach the Environment? Sources and Contamination Routes

Pharmaceutical residues enter the environment primarily through two routes: human and animal excretion, and the inappropriate disposal of expired or unused medications.

A high proportion of orally administered active ingredients is not metabolized by the body and is excreted as the active substance in urine — between 30 and 90% of the administered dose. These residues enter wastewater systems and can persist in surface water, groundwater, and sediments, as conventional treatment plants do not always achieve complete elimination.

In Europe, an estimated 80% of pharmaceutical waste from human consumption enters the environment through domestic wastewater, with 20% from hospitals. In the United States, a U.S. Geological Survey study found detectable concentrations of one or more pharmaceutical compounds in 80% of a sample of 139 streams across 30 states. A 2006 study identified concentrations of 28 pharmaceutical compounds in wastewater, surface water, and sediment treatment plants.

Drug use in animals adds another dimension to the problem. Antibiotics administered in the livestock industry — aimed at increasing production and reducing feed and water costs — are excreted directly into soil or surface waters. Lipid-soluble residues can bind strongly to soil particles, while more water-soluble residues can be carried by rainfall into groundwater and surface water streams.

Documented Ecological Impacts: From Pakistan’s Vultures to Fish Reproduction

The effects of pharmaceutical contamination on ecosystems go beyond hypothesis when documented cases are analyzed. Between 2000 and 2003, an unusual spike in mortality among a vulture species in Pakistan was recorded, placing it on the endangered species list. The cause: exposure to diclofenac through the consumption of carcasses of cattle previously treated with the drug, causing acute kidney failure and death. This is the first documented case of an ecological disaster caused by pharmaceutical contamination.

Another example is the disruption of fish reproduction through exposure to ethinyl estradiol — the synthetic estrogen in oral contraceptives — which affects the endocrine system of aquatic species. Although environmental concentrations tend to be low, concern centers on prolonged exposure to mixtures of active contaminants, whose combined effects have not been fully characterized.

The pharmacological groups generating the most concern are chemotherapeutics — due to the risk of generating resistant strains — and antineoplastic agents, due to their carcinogenic, mutagenic, and teratogenic properties.

Ecopharmacovigilance: The Emerging Regulatory Framework

The World Health Organization defines ecopharmacovigilance as the set of actions aimed at the detection, assessment, understanding, and prevention of the harmful effects of pharmaceutical compounds on the environment. Its role is to monitor the adverse effects of pharmaceuticals on humans and animals through environmental exposure.

Environmental Risk Assessment (ERA) is already a regulatory requirement in the new drug launch process in Europe and, in different forms, across other jurisdictions. The assessment is conducted in two phases: an initial exposure assessment (Phase I) and, if a threshold is exceeded, a detailed environmental effects assessment (Phase II).

For the pharmaceutical industry, this has concrete implications for product design, manufacturing processes, and waste management. CDMOs working on new chemical entities or generic formulations must be prepared to incorporate environmental impact considerations from early development stages.

The Role of the Pharmaceutical Industry in Reducing Contamination

Pharmaceutical environmental contamination has no single solution. It requires coordinated action across multiple levels:

• Educating healthcare professionals and patients on the importance of proper disposal of expired or unused medications.
• Pharmaceutical companies implementing strategies for proper drug disposal and recycling of pharmaceutical waste.
• Hospitals adopting pharmaceutical waste management practices aligned with international best standards.
• Designing molecules and formulations with a lower environmental footprint — an active area of research in green chemistry and pharmaceutical sustainability.

At Amarin Technologies, sustainability is part of our long-term perspective. Responsible pharmaceutical product development includes considering the full lifecycle of a compound — including its environmental fate once it has fulfilled its therapeutic function.

References

1. Kümmerer K. Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks. Springer, 2004.
2. European Medicines Agency. Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00). 2006.
3. Oaks JL et al. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature. 2004.
4. Kolpin DW et al. Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams. Environ Sci Technol. 2002.

Looking for a CDMO with a sustainability and environmental impact perspective integrated into development? Contact our Business Development team.